Modelling the dynamics of Anti-HBV Infection Therapy with Chinese Herbs

被引:0
|
作者
Ye, Yongan [1 ]
Min, Lequan [2 ]
机构
[1] Beijing Univ Chinese Med, Dongzhimen Hosp, Beijing 100700, Peoples R China
[2] Univ Sci & Technol Beijing, Appl Sci Sch, Beijing 100083, Peoples R China
关键词
hepatitis B; Chinese Herbs; anti-HBV infection therapy model; CHRONIC HEPATITIS-B; VIRUS-INFECTION; COMBINATION; LAMIVUDINE;
D O I
暂无
中图分类号
R318 [生物医学工程];
学科分类号
0831 ;
摘要
Effective treatment of chronic Hepatitis B virus (HBV) patients aims to prevent progression of chronic hepatitis B to cirrhosis, hepatocellular carcinoma, and eventually death. The use of mathematical modelling to explain the anti-HBV infection therapy has made a significant contribution for understanding the dynamics of host cells, viruses, the immune system. Chinese herbs are playing important roles for anti-HBV infection treatment. Recently a new type of Chinese herbs (NTCH) has been proved to be effective for anti-HBV infection therapy. Based on a patient's anti-hepatitis B virus (HBV) infection therapy clinical data with the NTCH and our previous modified basic virus infection model [1], a new differential equation model with an immune variable is set up. The numerical simulations of the model show that the evolution of the HBV DNA of the model is agreement with in the patient's clinic plasma HBV DNA levels. The model predicts that it needs to prolong the treatment time to 4.3 years to eliminate NTCH the HBV virus in the patient's infected hepatocytes. Otherwise earlier cessation of the therapy will make the patient's HBV DNA levels return rapidly.
引用
收藏
页码:83 / +
页数:2
相关论文
共 50 条
  • [41] Anti-HBV nucleoside analogs.
    Bisacchi, GS
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 1998, 216 : U313 - U313
  • [42] Nucleoside analogs as anti-HBV agents
    Zhou, Xiao-Xiong
    Littler, Eddy
    CURRENT TOPICS IN MEDICINAL CHEMISTRY, 2006, 6 (09) : 851 - 865
  • [43] Anti-HBV and HIV activities of Chinese herb Qing Yang Can (QYC).
    Chen, HS
    Chen, XH
    Zhang, XQ
    Mu, QZ
    Sheng, YM
    Zhou, QL
    ANTIVIRAL RESEARCH, 2000, 46 (01) : A63 - A63
  • [44] Telbivudine.: Anti-HBV agent
    Sorbera, LA
    Castañer, J
    Castañer, RM
    Bayés, M
    DRUGS OF THE FUTURE, 2003, 28 (09) : 870 - 879
  • [45] A mathematical model for Anti-HBV infection treatment with lamivudine and curative effect prediction
    Ji, Yu
    Li, Weidong
    Min, Lequan
    Dong, Xisong
    2007 IEEE INTERNATIONAL CONFERENCE ON CONTROL AND AUTOMATION, VOLS 1-7, 2007, : 595 - +
  • [46] Acute hepatitis B virus (HBV) infection in a repeat blood donor during anti-HBV vaccination
    Gessoni, Gianluca
    Barin, Paolo
    Salvadego, Maria Monica
    Favarato, Mose
    Valverde, Sara
    Marchiori, Giorgio
    BLOOD TRANSFUSION, 2012, 10 (03) : 384 - 386
  • [47] A controlled study of anti-HBV vaccine therapy in HBsAg healthy carriers.
    Pol, S
    Chaix, ML
    Nalpas, B
    Tiollais, P
    Michel, ML
    Brechot, C
    HEPATOLOGY, 2001, 34 (04) : 624A - 624A
  • [48] Adefovir dipivoxil -: Anti-HIV -: Anti-HBV
    不详
    DRUGS OF THE FUTURE, 2000, 25 (08) : 844 - 847
  • [49] Emtricitabine -: Coviracil® -: Anti-HIV -: Anti-HBV
    不详
    DRUGS OF THE FUTURE, 2001, 26 (08) : 798 - 800
  • [50] Anti-HBV effect of TAT-HBV targeted ribonuclease
    Jin Ding Jun Liu Cai-Fang Xue Wei-Dong Gong Ying-Hui Li Ya Zhao Department of Etiology
    World Journal of Gastroenterology, 2003, 9 (07) : 1525 - 1528